Business
AstraZeneca Invests $2 Billion in Summit to Pair Ivonescimab With Its Cancer ADCs
The drugmaker is buying a stake in the developer of the bispecific antibody that beat Keytruda in a lung cancer trial, and will test it alongside its antibody-drug conjugates in gastrointestinal cancers.